Hypophosphatemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP017 MIFTS: 49	Hypophosphatemia Categories: Bone diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Hypophosphatemia

MalaCards integrated aliases for Hypophosphatemia:

Name: Hypophosphatemia ¹² ³⁰ ⁵⁶ ⁶ ⁴⁵ ¹⁵ ⁷⁴

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050336

MeSH ⁴⁵ D017674

UMLS ⁷⁴ C0085682

Sources

Summaries for Hypophosphatemia

Disease Ontology : ¹² A phosphorus metabolism disease that is characterized by hypophosphatemia and the symptoms of osteomalacia including bone pain, skeletal deformities and osteoarthritis.

MalaCards based summary : Hypophosphatemia is related to dominant hypophosphatemia with nephrolithiasis or osteoporosis and hereditary hypophosphatemic rickets. An important gene associated with Hypophosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and FGF signaling pathway. The drugs Zinc and Insulin glargine have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : ⁷⁷ Hypophosphatemia is an electrolyte disorder in which there is a low level of phosphate in the blood.... more...

Sources

Related Diseases for Hypophosphatemia

Diseases related to Hypophosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)

#	Related Disease	Score	Top Affiliating Genes
1	dominant hypophosphatemia with nephrolithiasis or osteoporosis	33.6	SLC34A1 SLC9A3R1
2	hereditary hypophosphatemic rickets	33.3	SLC34A1 SLC34A3
3	hypophosphatemic rickets, autosomal dominant	32.8	FGF23 PHEX SFRP4 SLC34A3
4	hypophosphatemic rickets, x-linked dominant	31.9	DMP1 FGF23 KL PHEX PTH SLC34A1
5	tumoral calcinosis, hyperphosphatemic, familial, 1	31.6	FGF23 KL
6	metaphyseal chondrodysplasia, jansen type	31.4	FGF23 PTH
7	autosomal recessive hypophosphatemic rickets	31.4	DMP1 ENPP1 FGF23 PHEX
8	oncogenic osteomalacia	31.3	DMP1 FGF23 PHEX PTH SFRP4
9	hypophosphatemic rickets, x-linked recessive	30.9	CLCN5 DMP1 ENPP1 FGF23 PHEX SFRP4
10	fanconi syndrome	30.4	CLCN5 SLC34A1
11	enthesopathy	30.4	DMP1 FGF23 PHEX
12	mccune-albright syndrome	30.1	BGLAP FGF23
13	raine syndrome	30.1	DMP1 FGF23
14	hypophosphatasia	30.0	ENPP1 PHEX
15	nephrolithiasis, calcium oxalate	29.9	CLCN5 SLC34A1
16	fibrous dysplasia	29.9	BGLAP FGF23
17	arterial calcification of infancy	29.8	ENPP1 FGF23 PHEX
18	hyperparathyroidism	29.7	BGLAP FGF23 PHEX PTH
19	hypoparathyroidism	29.6	BGLAP FGF23 PTH
20	bone disease	29.5	BGLAP FGF23 PTH SLC34A3
21	hypophosphatemic rickets with hypercalciuria, hereditary	29.4	DMP1 ENPP1 FGF23 KL PHEX PTH
22	calcinosis	29.3	ENPP1 FGF23 KL PHEX
23	nephrocalcinosis	29.3	CLCN5 PHEX PTH SLC34A1 SLC34A3
24	hyperphosphatemia	29.3	FGF23 KL PHEX PTH SLC34A1
25	primary hyperparathyroidism	29.2	BGLAP FGF23 PTH
26	osteomalacia	29.1	BGLAP DMP1 FGF23 PHEX PTH SFRP4
27	bone resorption disease	29.1	BGLAP PTH
28	nephrolithiasis	29.0	CLCN5 FGF23 PTH SLC34A1 SLC34A3 SLC9A3R1
29	rickets	28.6	BGLAP CLCN5 DMP1 ENPP1 FGF23 PHEX
30	osteoporosis	28.5	BGLAP FGF23 KL PTH SLC34A1 SLC9A3R1
31	cutaneous-skeletal hypophosphatemia syndrome	12.4
32	hypophosphatemia, renal, with intracerebral calcifications	12.1
33	hypophosphatemic rickets, autosomal recessive, 1	12.0
34	nephrolithiasis/osteoporosis, hypophosphatemic, 1	11.8
35	hypophosphatemic rickets, autosomal recessive, 2	11.6
36	vitamin d hydroxylation-deficient rickets, type 1a	11.5
37	panostotic fibrous dysplasia	11.4
38	thyrotoxic periodic paralysis	11.3
39	exostoses, multiple, type i	11.0
40	fanconi renotubular syndrome 1	11.0
41	dent disease 1	11.0
42	lowe oculocerebrorenal syndrome	11.0
43	nephrolithiasis/osteoporosis, hypophosphatemic, 2	11.0
44	tumoral calcinosis, hyperphosphatemic, familial, 2	11.0
45	tumoral calcinosis, hyperphosphatemic, familial, 3	11.0
46	opsismodysplasia	10.3	FGF23 PHEX
47	anorexia nervosa	10.3
48	hypokalemia	10.3
49	leukemia	10.3
50	respiratory failure	10.3

Graphical network of the top 20 diseases related to Hypophosphatemia:

Sources

Symptoms & Phenotypes for Hypophosphatemia

MGI Mouse Phenotypes related to Hypophosphatemia:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.02	CLCN5 DMP1 ENPP1 FGF23 KL PHEX
2	homeostasis/metabolism	MP:0005376	10	CLCN5 DMP1 ENPP1 FGF23 KL PHEX
3	cardiovascular system	MP:0005385	9.98	DMP1 ENPP1 FGF23 KL PHEX PTH
4	digestive/alimentary	MP:0005381	9.85	FGF23 KL PHEX SFRP4 SLC34A3 SLC9A3R1
5	craniofacial	MP:0005382	9.8	CLCN5 DMP1 KL PHEX PTH
6	limbs/digits/tail	MP:0005371	9.7	DMP1 ENPP1 FGF23 KL PHEX PTH
7	renal/urinary system	MP:0005367	9.65	CLCN5 DMP1 ENPP1 FGF23 KL PHEX
8	skeleton	MP:0005390	9.36	CLCN5 DMP1 ENPP1 FGF23 KL PHEX

Sources

Drugs & Therapeutics for Hypophosphatemia

Drugs for Hypophosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Zinc

Approved, Investigational

Phase 4

7440-66-6

32051

Insulin glargine

Approved

Phase 4

160337-95-1

Iron

Approved, Experimental

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

7439-89-6, 15438-31-0

27284 23925

Iron isomaltoside 1000

Approved, Investigational

Phase 4

1370654-58-2

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Not Applicable,Early Phase 1

1406-16-2

Calcitriol

Approved, Nutraceutical

Phase 4,Not Applicable,Early Phase 1

32222-06-3

5280453 134070

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

7440-70-2

271

Chelating Agents

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Calciferol

Phase 4,Phase 3,Not Applicable,Early Phase 1

Vitamins

Phase 4,Phase 3,Not Applicable,Early Phase 1

Calcium, Dietary

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Trace Elements

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

Micronutrients

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Nutrients

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Locust bean gum

Phase 4

Polystyrene sulfonic acid

Phase 4

Hypoglycemic Agents

Phase 4

Insulin, Globin Zinc

Phase 4

insulin

Phase 4

Brewer's Yeast

Phase 4

Vasoconstrictor Agents

Phase 4,Phase 1,Phase 2,Early Phase 1

Ferric Compounds

Phase 4,Phase 3,Phase 2

Hematinics

Phase 4,Phase 3,Phase 2,Not Applicable

Parathyroid hormone

Approved, Investigational

Phase 3,Phase 1,Early Phase 1

9002-64-6

Cinacalcet

Approved

Phase 3,Phase 1,Not Applicable

226256-56-0

156419

Sorafenib

Approved, Investigational

Phase 3,Phase 1

284461-73-0

216239 406563

Sevelamer

Approved

Phase 3,Phase 2

52757-95-6

Emtricitabine

Approved, Investigational

Phase 3

143491-57-0

60877

Tenofovir

Approved, Experimental, Investigational

Phase 3,Phase 2

147127-20-6

464205

Ritonavir

Approved, Investigational

Phase 3

155213-67-5

392622

Lopinavir

Approved

Phase 3

192725-17-0

92727

Axitinib

Approved, Investigational

Phase 3

319460-85-0

6450551

Carboplatin

Approved

Phase 3,Phase 2

41575-94-4

10339178 38904 498142

leucovorin

Approved

Phase 3,Phase 2,Not Applicable

58-05-9

143 6006

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Crizotinib

Approved

Phase 3,Phase 1

877399-52-5

11626560 10366136 10366137 10366138 10366139 10366140 10366141

Pemetrexed

Approved, Investigational

Phase 3,Phase 2

150399-23-8, 137281-23-3

60843 446556

Adefovir dipivoxil

Approved, Investigational

Phase 3

142340-99-6

60871

Ergocalciferol

Approved, Nutraceutical

Phase 3,Not Applicable

50-14-6

5280793

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Not Applicable

59-30-3

6037

Adefovir

Investigational

Phase 3

106941-25-7

Mitogens

Phase 3,Phase 2,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Hormone Antagonists

Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Calcimimetic Agents

Phase 3,Phase 1,Not Applicable

Protein Kinase Inhibitors

Phase 3,Phase 2,Phase 1

Ergocalciferols

Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 107)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer	Unknown status	NCT01845922	Phase 4
2	Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients	Completed	NCT02065076	Phase 4	Sodium polystyrene sulfonate;Lactose with carob gum
3	Insulin in Total Parenteral Nutrition	Completed	NCT02706119	Phase 4	Subcutaneous glargine insulin;Regular insulin added to TPN bag
4	Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia	Recruiting	NCT03820518	Phase 4	Calcitriol
5	A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease	Recruiting	NCT03466983	Phase 4	Iron Isomaltoside;Ferric Carboxymaltose
6	A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer	Active, not recruiting	NCT02905539	Phase 4	Iron Isomaltoside 1000;Ferric Carboxymaltose
7	A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05)	Completed	NCT03237065	Phase 3	Iron Isomaltoside (Monofer);Ferric carboxymaltose
8	A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04)	Completed	NCT03238911	Phase 3	Iron isomaltoside (Monofer);Ferric carboxymaltose
9	Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)	Completed	NCT02537431	Phase 3
10	Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)	Completed	NCT02526160	Phase 3
11	Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets	Completed	NCT00417612	Phase 3	Paricalcitol
12	Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients	Completed	NCT00975000	Phase 3	Cinacalcet;Placebo
13	Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men	Completed	NCT00458393	Phase 3	daily TDF/FTC;Placebo
14	BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada	Completed	NCT00272779	Phase 3	ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV
15	Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets	Completed	NCT01237288	Phase 3	Z-521
16	Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer	Completed	NCT00678392	Phase 3	Axitinib (AG-013736);Sorafenib
17	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung	Completed	NCT01154140	Phase 3	treatment;treatment
18	Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)	Completed	NCT01300234	Phase 3	Tenofovir disoproxil fumarate (TDF) tablets;Adefovir dipivoxil (ADV) tablets
19	Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH	Recruiting	NCT03920072	Phase 3	Burosumab
20	Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis	Recruiting	NCT03346369	Phase 3	Lanthanum Carbonate
21	Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)	Active, not recruiting	NCT02915705	Phase 3	oral phosphate;active vitamin D
22	Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets	Active, not recruiting	NCT03581591	Phase 3
23	A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis	Active, not recruiting	NCT03427125	Phase 3	Tenapanor;Placebo;Sevelamer Carbonate
24	A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia	Active, not recruiting	NCT03233126	Phase 3	KRN23
25	Investigating a New Way of Giving Medicine to Newborn and Preterm Babies	Unknown status	NCT01676844	Phase 2	Oral thin film therapy (Potassium acid phosphate oral thin films);Standard therapy (Potassium acid phosphate oral solution)
26	An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia	Completed	NCT01571596	Phase 1, Phase 2	KRN23
27	A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia	Completed	NCT01340482	Phase 1, Phase 2	KRN23
28	Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)	Completed	NCT02163577	Phase 2
29	Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)	Completed	NCT02312687	Phase 2
30	Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding	Completed	NCT01307007	Phase 2	Ferric Carboxymaltose (FCM);Iron Dextran Injection
31	Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men	Completed	NCT00131677	Phase 2	tenofovir disoproxil fumarate;placebo
32	The Effects of Sevelamer Carbonate on Diabetic Nephropathy	Completed	NCT01493050	Phase 2	Sevelamer Carbonate;calcium carbonate
33	Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma	Completed	NCT01026493	Phase 1, Phase 2	temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
34	Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	Completed	NCT00699491	Phase 1, Phase 2	Temsirolimus
35	Cetuximab and Lenalidomide in Head and Neck	Completed	NCT01133665	Phase 2	Cetuximab and Lenalidomide
36	Growth Hormone Treatment in Children With Hypophosphatemic Rickets	Completed	NCT02720770	Phase 1, Phase 2	norditropine simplex
37	Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma	Completed	NCT00284141	Phase 2	Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
38	Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest	Completed	NCT01509040	Phase 1, Phase 2
39	BGJ398 for the Treatment of Tumor-Induced Osteomalacia	Recruiting	NCT03510455	Phase 2	BGJ398
40	Role Of Phosphorus And FGF 23 In Patients With Dent Disease	Recruiting	NCT02016235	Phase 1, Phase 2	Phosphorus Supplement
41	Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)	Active, not recruiting	NCT02750618	Phase 2
42	Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)	Terminated	NCT02447887	Phase 1, Phase 2	Ixazomib;Pegylated IFN-alpha 2b
43	Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)	Terminated	NCT00948389	Phase 1, Phase 2	Dasatinib;Lomustine
44	Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib	Terminated	NCT02226172	Phase 2	Glasdegib (PF-04449913);Placebo
45	A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population	Terminated	NCT01313663	Phase 2	pazopanib;pemetrexed
46	Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets	Unknown status	NCT00473187	Phase 1	somatropin
47	Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets	Unknown status	NCT00195936	Phase 1	Cinacalcet
48	A Study of KRN23 in X-linked Hypophosphatemia	Completed	NCT00830674	Phase 1	Placebo;KRN23
49	This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas	Completed	NCT02171260	Phase 1	Eribulin Mesylate
50	Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis	Completed	NCT01464931	Phase 1	Denosumab

Search NIH Clinical Center for Hypophosphatemia

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

dibasic potassium phosphate

dibasic sodium phosphate heptahydrate

ergocalciferol

monobasic potassium phosphate

potassium phosphate

potassium tripolyphosphate

sodium phosphate

sodium phosphate dihydrate

sodium phosphate, dibasic

sodium phosphate, dibasic, anhydrous

sodium phosphate, monobasic

sodium phosphate,monobasic,monohydrate

sodium phosphate,tribasic pwdr

tribasic sodium phosphate

Cochrane evidence based reviews: hypophosphatemia

Sources

Genetic Tests for Hypophosphatemia

Genetic tests related to Hypophosphatemia:

#	Genetic test	Affiliating Genes
1	Hypophosphatemia ³⁰

Sources

Anatomical Context for Hypophosphatemia

MalaCards organs/tissues related to Hypophosphatemia:

⁴²

Bone, Kidney, Liver, Myeloid, Lung, Prostate, Breast

Sources

Publications for Hypophosphatemia

Articles related to Hypophosphatemia:

(show top 50) (show all 852)

#	Title	Authors	Year
1	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. ( 30771083 )	Tufano A...Di Minno G	2019
2	Hypophosphatemia in a Malnourished Child: When Renal Fanconi Syndrome Does Not Stand for Refeeding Syndrome. ( 29746006 )	Runde J...Sentongo T	2019
3	Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome. ( 30171299 )	Chung TL...Chen CL	2019
4	Hypophosphatemia as a Predictor of Organ-Specific Complications Following Gastrointestinal Surgery: Analysis of 8034 Patients. ( 29955938 )	Sadot E...Jarnagin WR	2019
5	Hypophosphatemia as a sign of malnutrition in older hospitalized patients. ( 29967545 )	Pourhassan M...Wirth R	2019
6	Early Hypophosphatemia in High-Risk Preterm Infants: Efficacy and Safety of Sodium Glycerophosphate From First Day on Parenteral Nutrition. ( 30070716 )	Bustos Lozano G...Pall?s-Alonso CR	2019
7	Correction to: Hypophosphatemia as a Predictor of Organ-Specific Complications Following Gastrointestinal Surgery: Analysis of 8034 Patients. ( 30406321 )	Sadot E...Jarnagin WR	2019
8	Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia. ( 30607568 )	Hern?ndez-Fr?as O...Santos F	2019
9	Joint replacement in X-linked hypophosphatemia. ( 30662239 )	Mills ES...Macica CM	2019
10	Hypophosphatemia is Prevalent among Preterm Infants Less than 1,500 Grams. ( 30665240 )	Al-Wassia H...Fenton TR	2019
11	Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. ( 30682568 )	Zhang C...Xia W	2019
12	Elevated Bone Remodeling Markers of CTX and P1NP in Addition to Sclerostin in Patients with X-linked Hypophosphatemia: A Cross-Sectional Controlled Study. ( 30710161 )	Hansen S...Beck-Nielsen SS	2019
13	X-linked hypophosphatemia: Management and treatment prospects. ( 30711691 )	Lambert AS...Linglart A	2019
14	Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. ( 30772600 )	Thacher TD...Carpenter TO	2019
15	FGF23 and its role in X-linked hypophosphatemia-related morbidity. ( 30808384 )	Beck-Nielsen SS...M?kitie O	2019
16	First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia. ( 30828689 )	Cheong HI...Seino Y	2019
17	Oral symptoms and oral health-related quality of life of individuals with x-linked hypophosphatemia. ( 30904023 )	Hanisch M...Jung S	2019
18	Phosphate supplementation for hypophosphatemia during continuous renal replacement therapy in adults. ( 30909778 )	Song YH...Jo YI	2019
19	Identification of a p.Trp403* nonsense variant in PHEX causing X-linked hypophosphatemia by inhibiting p38 MAPK signaling. ( 30920082 )	Li W...Wang QK	2019
20	Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). ( 30928313 )	Rothenbuhler A...Linglart A	2019
21	Prosthetic rehabilitation of a patient with X-linked hypophosphatemia using dental implants: a case report and review of the literature. ( 31006822 )	James M...Roudsari RV	2019
22	A novel heterozygous mutation c.680A>G (p. N227S) in SLC34A1 gene leading to autosomal dominant hypophosphatemia: A case report. ( 31096470 )	Chen X...Yu X	2019
23	Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. ( 29696242 )	Reinert RB...Koenig RJ	2018
24	Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm. ( 30023010 )	Day AL...Saag KG	2018
25	Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic HRAS Mutation. ( 30373874 )	Park PG...Cheong HI	2018
26	Association Between Iron-Deficiency Anemia and Hypophosphatemia. ( 29031590 )	Kommalapati A...Tella SH	2018
27	Ibuprofen Abuse-A Case of Rhabdomyolysis, Hypokalemia, and Hypophosphatemia With Drug-Induced Mixed Renal Tubular Acidosis. ( 30197993 )	Patil S...Krause M	2018
28	Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures. ( 28880715 )	Coyac BR...Bardet C	2018
29	Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29068481 )	Bartko J...Klaushofer K	2018
30	Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia. ( 29083055 )	Tokarz D...Liu ES	2018
31	Aggressive Treatment of Life-Threatening Hypophosphatemia During Recovery From Fulminant Hepatic Failure: A Case Report. ( 29088996 )	Bissell BD...Thompson Bastin ML	2018
32	Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers. ( 29126251 )	Bergsland KJ...Worcester EM	2018
33	Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study. ( 29143140 )	Shanbhogue VV...Beck-Nielsen SS	2018
34	Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29281128 )	Tournis S...Terpos E	2018
35	Reply: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29314243 )	Bartko J...Klaushofer K	2018
36	X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. ( 29381780 )	Kinoshita Y...Fukumoto S	2018
37	Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. ( 29383408 )	Sullivan R...Insogna KL	2018
38	Prevention of hypophosphatemia during continuous renal replacement therapy-An overlooked problem. ( 29405468 )	Heung M...Mueller BA	2018
39	Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. ( 29460029 )	Chesher D...Murphy E	2018
40	Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3. ( 29505567 )	Acar S...Shi Y	2018
41	Suitability of oral administration of monosodium phosphate, disodium phosphate, and magnesium phosphate for the rapid correction of hypophosphatemia in cattle. ( 29572937 )	Cohrs I...Gr?nberg W	2018
42	Hypophosphatemia occurs with insulin administration during refeeding by total parenteral nutrition in rats. ( 29593193 )	Kawamura H...Ito M	2018
43	Hypophosphatemia and duration of respiratory failure and mortality in critically ill patients. ( 29687440 )	Federspiel CK...Bestle MH	2018
44	Impaired mineral quality in dentin in X-linked hypophosphatemia. ( 29745817 )	Coyac BR...Bardet C	2018
45	High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia. ( 29747838 )	St?hr R...Brandenburg V	2018
46	Hypercalcemia and hypophosphatemia among preterm infants receiving aggressive parenteral nutrition. ( 29756708 )	Brener Dik PH...L Mariani G	2018
47	Early hypophosphatemia in very low birth weight preterm infants. ( 29790700 )	Paj?k A...Szafra?ska A	2018
48	Burosumab Therapy in Children with X-Linked Hypophosphatemia. ( 29791829 )	Carpenter TO...Portale AA	2018
49	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. ( 29947083 )	Insogna KL...AXLES 1 Investigators	2018
50	Respiratory failure in a diabetic ketoacidosis patient with severe hypophosphatemia. ( 29969883 )	Choi HS...Kim HS	2018

Sources

Genes for Hypophosphatemia

Genes related to Hypophosphatemia (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	FGF23	Fibroblast Growth Factor 23	Protein Coding	57.81	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Gene name (show sections)	17891358 16941023 16691036 (more) 15838626 12187320 16644301 17227222 17359508 20513948 19449283 18854401 16261449 19684183 12414858 17943081 16369891 14687588 14968560 18310982 18936605 15579309 18288501 16551733 16337659 14733920 19121771 17699549 16012775 15742370 15595334 19366850 18922992 18230836 15930999 15199289 12711740 11409890 19808223 12590648 20177401 19555782 18037620 18037105 16011465 15995308 19615558 18480582 17906401 17976083 19609735 19219382 18234575 17352646 17635819 16969146 16352682 15630224 15596338 20107581 19578602 18950915 16481873 20219587 19581284 20458578 19933269 18396126 17906408 17565275 15483460 16751688
2	PHEX	Phosphate Regulating Endopeptidase Homolog X-Linked	Protein Coding	56.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Gene name (show sections)	10620182 10737991 8237485 (more) 12414538 14687588 9545633 10962341 12678920 19122271 11311133 15896324 18172553 9467015 15630224 15958652 17710565 16011465
3	SLC34A1	Solute Carrier Family 34 Member 1	Protein Coding	53.39	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries (show sections)	20031638
4	DMP1	Dentin Matrix Acidic Phosphoprotein 1	Protein Coding	51.29	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries (show sections)	19796717 17906408 17033625 (more) 17976082
5	SLC34A3	Solute Carrier Family 34 Member 3	Protein Coding	44.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	18996815
6	SFRP4	Secreted Frizzled Related Protein 4	Protein Coding	32.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16691036 12952927 16151791 (more) 18288501 19387319 12187320
7	PTH	Parathyroid Hormone	Protein Coding	32.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10372835 14962809 19449283
8	ENPP1	Ectonucleotide Pyrophosphatase/Phosphodiesterase 1	Protein Coding	30.88	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
9	SLC9A3R1	SLC9A3 Regulator 1	Protein Coding	30.66	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)
10	BGLAP	Bone Gamma-Carboxyglutamate Protein	Protein Coding	28.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8048355 15912787 1547718
11	CLCN5	Chloride Voltage-Gated Channel 5	Protein Coding	24.03	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
12	KL	Klotho	Protein Coding	23.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Hypophosphatemia

ClinVar genetic disease variations for Hypophosphatemia:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	SLC9A3R1	NM_004252.4(SLC9A3R1): c.673G> A (p.Glu225Lys)	single nucleotide variant	Likely benign	rs119486097	GRCh37	Chromosome 17, 72759575: 72759575
2	SLC9A3R1	NM_004252.4(SLC9A3R1): c.673G> A (p.Glu225Lys)	single nucleotide variant	Likely benign	rs119486097	GRCh38	Chromosome 17, 74763436: 74763436

Sources

Expression for Hypophosphatemia

Search GEO for disease gene expression data for Hypophosphatemia.

Sources

Pathways for Hypophosphatemia

Pathways related to Hypophosphatemia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Parathyroid hormone synthesis, secretion and action ³⁸	11.19	BGLAP FGF23 KL PTH SLC34A1 SLC34A3
2	FGF signaling pathway ¹	10.99	BGLAP FGF23
3	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²³	10.91	BGLAP PTH
4	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²³	10.75	BGLAP PTH
5	Osteoblast Signaling ¹	10.28	BGLAP FGF23 PTH

Sources

GO Terms for Hypophosphatemia

Cellular components related to Hypophosphatemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.8	BGLAP ENPP1 FGF23 KL PTH SFRP4
2	extracellular region	GO:0005576	9.8	BGLAP DMP1 ENPP1 FGF23 KL PTH
3	apical plasma membrane	GO:0016324	9.46	KL SLC34A1 SLC34A3 SLC9A3R1
4	brush border membrane	GO:0031526	9.13	SLC34A1 SLC34A3 SLC9A3R1
5	vesicle	GO:0031982	8.92	BGLAP SLC34A1 SLC34A3 SLC9A3R1

Biological processes related to Hypophosphatemia according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular protein metabolic process	GO:0044267	9.78	DMP1 FGF23 SLC34A1
2	skeletal system development	GO:0001501	9.75	BGLAP PHEX PTH
3	ossification	GO:0001503	9.71	BGLAP DMP1 SLC34A1
4	positive regulation of bone mineralization	GO:0030501	9.6	KL PTH
5	response to cadmium ion	GO:0046686	9.59	PTH SLC34A1
6	response to lead ion	GO:0010288	9.58	PTH SLC34A1
7	regulation of bone mineralization	GO:0030500	9.58	BGLAP ENPP1 FGF23
8	phosphate-containing compound metabolic process	GO:0006796	9.57	ENPP1 FGF23
9	response to growth hormone	GO:0060416	9.56	PHEX SLC34A1
10	response to magnesium ion	GO:0032026	9.55	FGF23 SLC34A1
11	response to vitamin D	GO:0033280	9.54	BGLAP PHEX PTH
12	phosphate ion transport	GO:0006817	9.52	SLC34A1 SLC34A3
13	sodium-dependent phosphate transport	GO:0044341	9.51	SLC34A1 SLC34A3
14	cellular response to vitamin D	GO:0071305	9.5	BGLAP FGF23 PHEX
15	positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway	GO:0090080	9.49	FGF23 KL
16	response to parathyroid hormone	GO:0071107	9.48	PTH SLC34A1
17	response to sodium phosphate	GO:1904383	9.46	FGF23 PHEX
18	biomineral tissue development	GO:0031214	9.46	BGLAP DMP1 ENPP1 PHEX
19	bone mineralization	GO:0030282	9.43	BGLAP PHEX
20	cellular response to parathyroid hormone stimulus	GO:0071374	9.43	FGF23 PHEX SLC34A1
21	phosphate ion homeostasis	GO:0055062	9.26	FGF23 PTH SFRP4 SLC34A1
22	cellular phosphate ion homeostasis	GO:0030643	9.02	ENPP1 FGF23 SLC34A1 SLC34A3 SLC9A3R1

Molecular functions related to Hypophosphatemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	fibroblast growth factor receptor binding	GO:0005104	9.16	FGF23 KL
2	sodium:phosphate symporter activity	GO:0005436	8.96	SLC34A1 SLC34A3
3	sodium-dependent phosphate transmembrane transporter activity	GO:0015321	8.62	SLC34A1 SLC34A3

Sources

Sources for Hypophosphatemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Hypophosphatemia

Aliases & Classifications for Hypophosphatemia

MalaCards integrated aliases for Hypophosphatemia:

Classifications:

External Ids:

Summaries for Hypophosphatemia

Related Diseases for Hypophosphatemia

Diseases related to Hypophosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Hypophosphatemia:

Symptoms & Phenotypes for Hypophosphatemia

MGI Mouse Phenotypes related to Hypophosphatemia:

Drugs & Therapeutics for Hypophosphatemia

Drugs for Hypophosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cochrane evidence based reviews: hypophosphatemia

Genetic Tests for Hypophosphatemia

Genetic tests related to Hypophosphatemia:

Anatomical Context for Hypophosphatemia

MalaCards organs/tissues related to Hypophosphatemia:

Publications for Hypophosphatemia

Articles related to Hypophosphatemia:

Genes for Hypophosphatemia

Genes related to Hypophosphatemia (0 elite genes):

Variations for Hypophosphatemia

ClinVar genetic disease variations for Hypophosphatemia:

Expression for Hypophosphatemia

Pathways for Hypophosphatemia

Pathways related to Hypophosphatemia according to GeneCards Suite gene sharing:

GO Terms for Hypophosphatemia

Cellular components related to Hypophosphatemia according to GeneCards Suite gene sharing:

Biological processes related to Hypophosphatemia according to GeneCards Suite gene sharing:

Molecular functions related to Hypophosphatemia according to GeneCards Suite gene sharing:

Sources for Hypophosphatemia

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :